Charles Schwab Investment Management Inc Avalo Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.0 - $10.45 $235,248 - $819,447	-78,416 Reduced 57.93%	56,953 $29,000
Q1 2022 May 13, 2022	SELL	$7.57 - $21.72 $154,503 - $443,305	-20,410 Reduced 13.1%	135,369 $99,000
Q4 2021 Feb 11, 2022	BUY	$19.68 - $28.68 $453,919 - $661,504	23,065 Added 17.38%	155,779 $265,000
Q3 2021 Nov 16, 2021	BUY	$26.16 - $40.68 $3.47 Million - $5.4 Million	132,714 New	132,714 $290,000

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $84.9M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.